Lv5
1270 积分 2025-02-14 加入
A renaissance in targeting the PI3K/AKT/mTOR pathway
2天前
已完结
Accelerating progress in immune cell therapy for solid tumours
2天前
已完结
Advances in the management of metastatic gastric cancer: current strategies and emerging therapeutics
7天前
已完结
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
27天前
已完结
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study
27天前
已完结
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study
27天前
已完结
Tecotabart vedotin in Claudin 18.2-positive advanced gastric/gastroesophageal junction cancer: A Bayesian phase 1/2 clinical trial
1个月前
已完结
Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trial
7个月前
已完结
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
7个月前
已完结
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results
8个月前
已完结
皖公网安备34019202002308
